Cargando…

Linagliptin and Empagliflozin Inhibit Microtubule Affinity Regulatory Kinase 4: Repurposing Anti-Diabetic Drugs in Neurodegenerative Disorders Using In Silico and In Vitro Approaches

[Image: see text] Type 2 diabetes mellitus (T2DM) and Alzheimer’s disease (AD) are significant public health burdens. Many studies have revealed the possibility of common pathophysiology between T2DM and AD. Thus, in recent years, studies deciphering the action mechanism of anti-diabetic drugs with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Atiya, Akhtar, Das Gupta, Debarati, Alsayari, Abdulrhman, Alrouji, Mohammed, Alotaibi, Abdulmajeed, Sharaf, Sharaf E., Abdulmonem, Waleed Al, Alorfi, Nasser M., Abdullah, K. M., Shamsi, Anas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2023
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9948186/ https://www.ncbi.nlm.nih.gov/pubmed/36844587 http://dx.doi.org/10.1021/acsomega.2c06634

Ejemplares similares

Unlocking potential inhibitors for Bruton's tyrosine kinase through in-silico drug repurposing strategies
por: Alrouji, Mohammed, et al.
Publicado: (2023)

Mechanistic Insight into the Binding of Huperzine a with Human Transferrin: Computational, Spectroscopic and Calorimetric Approaches
por: Atiya, Akhtar, et al.
Publicado: (2022)

Insight into the Biological Roles and Mechanisms of Phytochemicals in Different Types of Cancer: Targeting Cancer Therapeutics
por: Majrashi, Taghreed A., et al.
Publicado: (2023)

Inhibition of Microtubule Affinity Regulating Kinase 4 by Metformin: Exploring the Neuroprotective Potential of Antidiabetic Drug through Spectroscopic and Computational Approaches
por: Ashraf, Ghulam Md., et al.
Publicado: (2022)

Correction: Ashraf et al. Inhibition of Microtubule Affinity Regulating Kinase 4 by Metformin: Exploring the Neuroprotective Potential of Antidiabetic Drug through Spectroscopic and Computational Approaches. Molecules 2022, 27, 4652
por: Ashraf, Ghulam Md., et al.
Publicado: (2023)

Identification of 11-Hydroxytephrosin and Torosaflavone A as Potential Inhibitors of 3-Phosphoinositide-Dependent Protein Kinase 1 (PDPK1): Toward Anticancer Drug Discovery
por: Atiya, Akhtar, et al.
Publicado: (2022)

Empagliflozin/linagliptin: Euglycaemic diabetic ketoacidosis: case report
Publicado: (2021)

Empagliflozin/linagliptin single‐tablet combination: first‐in‐class treatment option
por: Woo, V.
Publicado: (2015)

Comparison of effects of Empagliflozin and Linagliptin on renal function and glycaemic control: a double-blind, randomized clinical trial
por: Mohammad zadeh Gharabaghi, Mohammad Amin, et al.
Publicado: (2022)

Investigating the Effect of Cigarette Smoking on Serum Uric Acid Levels in Multiple Sclerosis Patients: A Cross Sectional Study
por: Alrouji, Mohammed, et al.
Publicado: (2023)

Combination of Linagliptin and Empagliflozin Preserves Cardiac Systolic Function in an Ischemia-Reperfusion Injury Mice With Diabetes Mellitus
por: Ideishi, Akihito, et al.
Publicado: (2021)

Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin
por: Zeng, Yi-Hong, et al.
Publicado: (2022)

Early combination therapy of empagliflozin and linagliptin exerts beneficial effects on pancreatic β cells in diabetic db/db mice
por: Fushimi, Yoshiro, et al.
Publicado: (2021)

Initial Combination Empagliflozin and Linagliptin Improves Kidney Fibrotic Marker in Patients With Type 2 Diabetes: A Randomized Controlled Trial
por: Sathavarodom, Nattapol, et al.
Publicado: (2021)

Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting
por: Lee, Yueh-Ting, et al.
Publicado: (2021)

Overcoming obstacles to repurposing for neurodegenerative disease
por: Shineman, Diana W, et al.
Publicado: (2014)

Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice
por: Takahashi, Hiroyuki, et al.
Publicado: (2019)

Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine
por: Ott, Christian, et al.
Publicado: (2021)

Analytical quality by design based on design space in reversed-phase-high performance liquid chromatography analysis for simultaneous estimation of metformin, linagliptin and empagliflozin
por: Marie, Aya A., et al.
Publicado: (2022)

Neuroprotective Properties of Linagliptin: Focus on Biochemical Mechanisms in Cerebral Ischemia, Vascular Dysfunction and Certain Neurodegenerative Diseases
por: Wiciński, Michał, et al.
Publicado: (2019)

SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in db/db Mice, a Model of Type 2 Diabetes
por: Korbut, Anton I., et al.
Publicado: (2020)

The clinical application of linagliptin in Asians
por: Cao, Chu-qing, et al.
Publicado: (2015)

Linagliptin: from bench to bedside
por: Doupis, John
Publicado: (2014)

The Effects of the 2019 Novel Coronavirus Disease (COVID-19) Outbreak on Academic Staff Members: A Case Study of a Pharmacy School in Saudi Arabia
por: Almaghaslah, Dalia, et al.
Publicado: (2020)

Using a Global Systematic Framework Tool to Identify Pharmacy Workforce Development Needs: A National Case Study on Saudi Arabia
por: Almaghaslah, Dalia, et al.
Publicado: (2021)

Genus Ziziphus for the treatment of chronic inflammatory diseases
por: Alsayari, Abdulrhman, et al.
Publicado: (2021)

Using Design Thinking Method in Academic Advising: A Case Study in a College of Pharmacy in Saudi Arabia
por: Almaghaslah, Dalia, et al.
Publicado: (2022)

Academic Help-Seeking Behaviours of Undergraduate Pharmacy Students in Saudi Arabia: Usage and Helpfulness of Resources
por: Almaghaslah, Dalia, et al.
Publicado: (2022)

A cross-sectional study on Saudi pharmacists working as medical representatives: What attracted them and what is keeping them in this sector—Misconceptions and reality
por: Almaghaslah, Dalia, et al.
Publicado: (2023)

Potential Pharmacological Applications of Nigella Seeds with a Focus on Nigella sativa and Its Constituents against Chronic Inflammatory Diseases: Progress and Future Opportunities
por: Wahab, Shadma, et al.
Publicado: (2023)

Current Drug Repurposing Strategies for Rare Neurodegenerative Disorders
por: Shah, Sweta, et al.
Publicado: (2021)

Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
por: Jojima, Teruo, et al.
Publicado: (2016)

Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria
por: Xu, Yixiang, et al.
Publicado: (2023)

Is the combination of linagliptin and allopurinol better prophylaxis against post-contrast acute kidney injury? A multicenter prospective randomized controlled study
por: Fayed, Ahmed, et al.
Publicado: (2023)

Incorrect description of mode of excretion of linagliptin
por: Woerle, Hans-Juergen, et al.
Publicado: (2010)

Acute Kidney Injury Associated with Linagliptin
por: Nandikanti, Deepak K., et al.
Publicado: (2016)

Linagliptin-Associated Alopecia and Bullous Pemphigoid
por: Someili, Ali, et al.
Publicado: (2019)

Analytical Enantio-Separation of Linagliptin in Linagliptin and Metformin HCl Dosage Forms by Applying Two-Level Factorial Design
por: Jadhav, Sushant B., et al.
Publicado: (2016)

Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders()
por: Khatri, Dharmendra Kumar, et al.
Publicado: (2021)

Empagliflozin induced euglycemic diabetic ketoacidosis. A case reports
por: Altowayan, Waleed M.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e2t27d8nf305m11fqmhe5a59vn